IHC using anti-PD-L1 antibody clone 22C3 revealed that 71.3%, 51.2%, and 38.1% of human squamous cell carcinomas, renal cancers, and breast cancers, respectively, were PD-L1-positive [38]. Here, CD274 is linked to breast carcinoma.